From a future perspective, additional validation of the identified biomarkers including EZH2, PCNA, STAT5A and TYMS, that could be considered as p53-downstream genes will help in the diagnosis and prognosis of HPV+ HNSCC. The gene discussed is PCNA; the disease is head and neck squamous cell carcinoma.